Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design

Source Motley_fool

Recursion Pharmaceuticals (NASDAQ:RXRX), an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Trading volume reached 39.4M shares, coming in about 65% above its three-month average of 23.8M shares. Recursion Pharmaceuticals IPO'd in 2021 and has fallen 91% since going public.

How the markets moved today

S&P 500 (SNPINDEX:^GSPC) closed at 7,323, down 0.24%, while Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 24,430, up 0.42%. In biotechnology: AI-enabled drug discovery and clinical-stage therapeutics, Schrödinger (NASDAQ:SDGR) closed at $27.20, up 6.00%, and Relay Therapeutics (NASDAQ:RLAY) closed at $16.51, up 0.24%.

What this means for investors

Recursion shares are up 4% today after it aligned with the FDA on a Phase III trial design for 200 adults with familial adenomatous polyposis. The disease currently has no approved therapies, making Recursion's REC-4881 one of the first AI-enabled treatments to advance toward a Phase III trial.

Recursion believes there are over 50,000 patients with familial adenomatous polyposis in the U.S. and E.U., representing a $15 billion market opportunity for the $1.7 billion company. The FDA accepted 10 mm or larger polyp excision as part of its primary endpoint of event-free survival, which could be a win for RXRX stock, as it shouldn't have to run a longer, costlier trial waiting for adverse events to develop further.

While today's development is great progress for the stock, the results of the Phase III trial itself remain paramount, as success with REC-4881 would serve as a proof of concept not just for Recursion but for its AI platform. The Phase III trial won't begin until the second half of 2027, however, so interested investors need to be uber-patient and risk-tolerant before considering this stock.

Should you buy stock in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Schrödinger. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: XAU/USD Breaks Below $3,800 | Mitrade AUGold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
Author  Mitrade Team
15 hours ago
Gold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
placeholder
Market News Today Australia: Gold Below US$3,900, US Stocks Fall as Nvidia Delivers Strong EarningsUS retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
Author  Mitrade Team
20 hours ago
US retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
Yesterday 08: 50
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
Yesterday 03: 24
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
placeholder
Berkshire Hathaway's Only New Q3 Position Is a Company Few Investors RecognizeBerkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
Author  Beincrypto
Yesterday 02: 51
Berkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
goTop
quote